CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $4.2 million grant from the Arizona Governor’s Office to support the creation of the world’s first digital biosignatures laboratory focused on neurodegenerative disorders.
Collaboration Focuses on CND’s Groundbreaking Syn-One Test® that Aids in the Diagnosis of Parkinson’s Disease and Other Neurodegenerative Disorders
Grant Supports the Evaluation of CND’s Skin Biopsy Test to Identity Early Signs of Parkinson’s Disease and Other Neurodegenerative Disorders and Serve as an Effective Marker for Future Treatments
CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $2.4 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH).
Will Advance the Company’s Technology Designed to Aid the Diagnosis of Parkinson’s Disease and Other Neurological Disorders
Strong market adoption of Syn-One Test™ to help clinicians diagnose Parkinson’s Disease and other neurological disorders
Enrique Carrazana, MD Brings Deep Expertise in Neuroscience and the Life Sciences Industry to Support the Company’s Mission
Strategic Collaboration Educates Neurology Community About Syn-One Test™
Innovators of the Syn-One Test™ Building Market Presence and Infrastructure
Poised for Growth After Successfully Launching First Skin-Based Test for Parkinson’s